ZW9293A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
ZW9293A1
ZW9293A1 ZW9293A ZW9293A ZW9293A1 ZW 9293 A1 ZW9293 A1 ZW 9293A1 ZW 9293 A ZW9293 A ZW 9293A ZW 9293 A ZW9293 A ZW 9293A ZW 9293 A1 ZW9293 A1 ZW 9293A1
Authority
ZW
Zimbabwe
Prior art keywords
chemical compounds
cpg2
prodrugs
adept
carboxypeptidase
Prior art date
Application number
ZW9293A
Other languages
English (en)
Inventor
Philip John Burke
Robert Ian Dowell
Caroline Joy Springer
Anthony Brian Mauger
Original Assignee
Zeneca Ltd
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215636A external-priority patent/GB9215636D0/en
Priority claimed from GB939310884A external-priority patent/GB9310884D0/en
Application filed by Zeneca Ltd, Cancer Res Campaign Tech filed Critical Zeneca Ltd
Publication of ZW9293A1 publication Critical patent/ZW9293A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66Methanesulfonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZW9293A 1992-07-23 1993-07-23 Chemical compounds ZW9293A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929215636A GB9215636D0 (en) 1992-07-23 1992-07-23 Chemical compounds
GB939310884A GB9310884D0 (en) 1993-05-26 1993-05-26 Chemical compounds

Publications (1)

Publication Number Publication Date
ZW9293A1 true ZW9293A1 (en) 1994-03-30

Family

ID=26301303

Family Applications (1)

Application Number Title Priority Date Filing Date
ZW9293A ZW9293A1 (en) 1992-07-23 1993-07-23 Chemical compounds

Country Status (25)

Country Link
US (6) US5405990A (fr)
EP (1) EP0651740B1 (fr)
JP (1) JP3541037B2 (fr)
KR (1) KR100268654B1 (fr)
AT (1) ATE172450T1 (fr)
AU (1) AU681349B2 (fr)
CA (1) CA2101104C (fr)
CZ (1) CZ287028B6 (fr)
DE (1) DE69321729T2 (fr)
DK (1) DK0651740T3 (fr)
ES (1) ES2123662T3 (fr)
FI (1) FI115048B (fr)
GB (1) GB9314960D0 (fr)
HK (1) HK1002683A1 (fr)
HU (1) HUT69288A (fr)
IL (1) IL106459A (fr)
MY (1) MY111635A (fr)
NZ (1) NZ254864A (fr)
PH (1) PH30004A (fr)
PL (1) PL174617B1 (fr)
RU (1) RU2129542C1 (fr)
SK (1) SK281338B6 (fr)
TW (1) TW272971B (fr)
WO (1) WO1994002450A1 (fr)
ZW (1) ZW9293A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
ATE361759T1 (de) * 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9426133D0 (en) * 1994-12-23 1995-02-22 Zeneca Ltd Chemical compounds
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
JP4812167B2 (ja) * 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
WO2001078626A1 (fr) 2000-04-13 2001-10-25 Sts Biopolymers, Inc. Dispositifs de liberation ciblee d'agents therapeutiques et procedes de fabrication et de mise en oeuvre de tels dispositifs
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7183319B2 (en) * 2000-07-26 2007-02-27 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma
GB0102239D0 (en) * 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
JP2005516011A (ja) * 2001-12-13 2005-06-02 ランバクシー ラボラトリーズ リミテッド 結晶二水化セフニディールカリウム
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NZ537690A (en) 2002-07-15 2009-07-31 Univ Texas Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
EP1654221A2 (fr) * 2003-06-10 2006-05-10 Smithkline Beecham Corporation Modulateurs de recepteurs androgene, glucocorticoide, mineralcorticoide, progesterone bases sur des derives d' aniline
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (fr) 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
JP5116686B2 (ja) 2005-10-26 2013-01-09 メダレックス インコーポレイテッド Cc−1065類似体の調製方法及び調製用化合物
CA2627190A1 (fr) 2005-11-10 2007-05-24 Medarex, Inc. Composes et conjugues cytotoxiques
EP2097097B1 (fr) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Anticorps, en particulier anticorps humains, se liant a cd22 et utilisations de ceux-ci
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Cd70に結合するヒト抗体およびその使用
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2121667B1 (fr) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Liants chimiques avec acides aminés uniques et conjugués de ceux-ci
KR101502267B1 (ko) 2007-11-09 2015-03-18 페레그린 파마수티컬즈, 인크 항-vegf 항체 조성물 및 방법
WO2014080251A1 (fr) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
CA2991973C (fr) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
JP6843977B2 (ja) * 2017-05-15 2021-03-17 旭化成株式会社 イソシアネートの製造方法
CN113845448B (zh) * 2021-10-20 2023-07-07 厦门大学 一种放射性18f标记化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) * 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
GB8920011D0 (en) * 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
US5633158A (en) * 1991-10-23 1997-05-27 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
HU9500145D0 (en) 1995-03-28
IL106459A0 (en) 1994-11-11
WO1994002450A1 (fr) 1994-02-03
PL307226A1 (en) 1995-05-15
MY111635A (en) 2000-10-31
FI950230A (fi) 1995-01-19
US5958971A (en) 1999-09-28
FI950230A0 (fi) 1995-01-19
EP0651740A1 (fr) 1995-05-10
HUT69288A (en) 1995-09-28
JP3541037B2 (ja) 2004-07-07
RU95105246A (ru) 1997-04-27
PL174617B1 (pl) 1998-08-31
CA2101104C (fr) 2007-01-23
IL106459A (en) 1998-02-08
ATE172450T1 (de) 1998-11-15
GB9314960D0 (en) 1993-09-01
US6277880B1 (en) 2001-08-21
DE69321729T2 (de) 1999-03-18
KR100268654B1 (ko) 2000-10-16
AU681349B2 (en) 1997-08-28
DK0651740T3 (da) 1999-06-28
HK1002683A1 (en) 1998-09-11
SK281338B6 (sk) 2001-02-12
US5405990A (en) 1995-04-11
NZ254864A (en) 1996-11-26
RU2129542C1 (ru) 1999-04-27
CA2101104A1 (fr) 1994-01-24
AU4715693A (en) 1994-02-14
CZ287028B6 (en) 2000-08-16
EP0651740B1 (fr) 1998-10-21
JPH07509461A (ja) 1995-10-19
FI115048B (fi) 2005-02-28
US5714148A (en) 1998-02-03
US5587161A (en) 1996-12-24
DE69321729D1 (de) 1998-11-26
CZ15195A3 (en) 1995-11-15
TW272971B (fr) 1996-03-21
US5660829A (en) 1997-08-26
PH30004A (en) 1996-10-29
SK6995A3 (en) 1995-07-11
ES2123662T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
PH30004A (en) Chemical compounds
AU6171796A (en) Prodrugs of pharmaceuticals with improved bioavailability
AU5022593A (en) Prodrugs, their preparation and use as pharmaceuticals
PT88187A (pt) Metodo para a distribuicao de agentes citotoxicos para celulas tumorais mediante administracao de conjugados de anticorpo-enzima em associacao com profarmacos com actividade citotoxica
MX9601994A (es) Profarmacos de derivados de paclitaxel.
AU633867B2 (en) Delivery of cytotoxic agents
AU7999787A (en) Active compounds for use in the treatment of tumors
AU1469097A (en) Pharmaceutical compounds
EP0317956A3 (fr) Prodrogues anti-tumeur
AU4586800A (en) Chemical compounds